beta-2 Microglobulin antibody (AA 21-119)

Catalog No. ABIN5776062

This Mouse Monoclonal antibody specifically detects beta-2 Microglobulin in WB, FACS, ELISA, IF and ICC. It exhibits reactivity toward Human.

Quick Overview for beta-2 Microglobulin antibody (AA 21-119) (ABIN5776062)

Target: beta-2 Microglobulin (B2M) (beta-2-Microglobulin (B2M))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This beta-2 Microglobulin antibody is un-conjugated

Application: Western Blotting (WB), Flow Cytometry (FACS), ELISA, Immunofluorescence (IF), Immunocytochemistry (ICC)

Clone: AT101F10

Product Details anti-beta-2 Microglobulin Antibody

Binding Specificity: AA 21-119

Immunogen: Recombinant human B2M (21-119aa) purified from E. coli

Isotype: IgG2b kappa

Application Details

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: Can be stored at +2°C to +8°C for 1 week. For long term storage, aliquot and store at -20°C to -80°C. Avoid repeated freezing and thawing cycles.

Target Details for beta-2 Microglobulin

Target: beta-2 Microglobulin (B2M) (beta-2-Microglobulin (B2M))

Alternative Name: beta 2-Microglobulin/B2M

Background: Beta2 microglobulin, also known as B2M, is a component of MHC class I molecules, Involved in the presentation of peptide antigens to the immune system. B2M is a protein found on the surface of many cells and plentiful on the surface of white blood cells. Increased production or destruction of these cells causes B2M levels in the blood to increase. This increase is seen in people with cancers involving white blood cells, but it is particularly meaningful in people newly diagnosed with multiple myeloma. Multiple myeloma is a malignancy (cancer) of a certain kind of white blood cell, called a plasma cell. B2M Testing is done primarily when evaluating a person for certain kinds of cancer affecting white blood cells including chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and multiple myeloma or kidney disease.

NCBI Accession: NP_004039

Pathways: TCR Signaling, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process